Search hospitals

>

Ohio

>

Cleveland

Cleveland Clinic Taussig Cancer Center

Claim this profile

Cleveland, Ohio 44106

Global Leader in Brain Tumor

Global Leader in Lymphoma

Conducts research for Leukemia

Conducts research for Cancer

Conducts research for Breast Cancer

769 reported clinical trials

45 medical researchers

Photo of Cleveland Clinic Taussig Cancer Center in ClevelandPhoto of Cleveland Clinic Taussig Cancer Center in ClevelandPhoto of Cleveland Clinic Taussig Cancer Center in Cleveland

Summary

Cleveland Clinic Taussig Cancer Center is a medical facility located in Cleveland, Ohio. This center is recognized for care of Brain Tumor, Lymphoma, Leukemia, Cancer, Breast Cancer and other specialties. Cleveland Clinic Taussig Cancer Center is involved with conducting 769 clinical trials across 479 conditions. There are 45 research doctors associated with this hospital, such as David Peereboom, MD, Dale Shepard, Aaron Gerds, MD, MS, and Brian Gastman, MD.

Area of expertise

1

Brain Tumor

Global Leader

Cleveland Clinic Taussig Cancer Center has run 93 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
MGMT positive
Stage III
2

Lymphoma

Global Leader

Cleveland Clinic Taussig Cancer Center has run 70 trials for Lymphoma. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Top PIs

Clinical Trials running at Cleveland Clinic Taussig Cancer Center

Cancer

Acute Myeloid Leukemia

Brain Tumor

Glioblastoma

Colorectal Cancer

Lung Cancer

Bladder Cancer

Ovarian Cancer

Solid Tumors

Breast Cancer

Image of trial facility.

Ivosidenib + Venetoclax +/- Azacitidine

for Leukemia

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.

Recruiting

3 awards

Phase 1 & 2

Image of trial facility.

Disulfiram + Copper Gluconate + Liposomal Doxorubicin

for Sarcoma

This trial tests a new treatment combining a drug for alcoholism, a copper supplement, and a special chemotherapy for patients whose sarcomas came back or didn't respond to initial treatment. The goal is to make the chemotherapy work better by stopping the cancer from resisting it. Researchers are checking if this combination is safe and effective.

Recruiting

3 awards

Phase 1

Image of trial facility.

18F-Clofarabine PET Imaging

for Cancer

The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.

Recruiting

1 award

Phase < 1

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cleveland Clinic Taussig Cancer Center?

Where is Cleveland Clinic Taussig Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Cleveland Clinic Taussig Cancer Center accept?

What awards or recognition has Cleveland Clinic Taussig Cancer Center received?